title: Clinical antiangiogenic effect of recombinant adenovirus-p53 combined with hyperthermia for advanced cancer.
abstract: OBJECTIVE
  To assess the safety and clinical antiangiogenic effect of recombinant adenovirus-p53 (rAd-p53) combined with hyperthermia plus or not plus radiotherapy in advanced cancer.
  
  
  METHODS
  Expression of Vascular epithelial growth factor (VEGF) after intratumoral injection of rAd-p53 was assayed by immunohistochemistry (IHC) imaging. Forty-four patients with advanced cancer were enrolled into this clinical study. The patients were intratumorally injected with rAd-p53 (Gendicine) at a dose of 1×10(12) vp once a week, with a total of 4-54 (mean 7.7) times. Total of 4-29 (mean 8.5) times of hyperthermia was given to the patients. Among the 44 patients, 30 patients were concurrently added with radiotherapy of a total dose 30-76 Gy/15-38 f/3-8 w (mean 58 Gy).
  
  
  RESULTS
  Before and after intratumoral injection of rAd-p53, the VEGF IHC positive cell scores were 2.80 and 1.50, respectively (P=0.031). The treatment of rAd-p53 combined with hyperthermia plus or not plus radiotherapy in advanced cancer achieved CR rate of 13.60% (6/44), and PR rate of 29.6% (13/44), and thus the effective rate was 43.2%. In addition to 6 patients with CR, 19 patients (19/38, 50.0%) had low density area (LDA) of more than 50% area on CT image within tumor indicating tumor tissue necrosis.
  
  
  CONCLUSIONS
  Our data indicate that rAd-p53 inhibits VEGF expression and angiogenesis, and promotes tumor necrosis and shrinkage induced by hyperthermia plus or not plus radiotherapy in advanced cancer.
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Departure of Radiotherapy, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Xiaofan
authors.initials: X
authors.lastname: Li
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Departure of Radiotherapy, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Shaowen
authors.initials: S
authors.lastname: Xiao
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Departure of Radiotherapy, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Yongheng
authors.initials: Y
authors.lastname: Li
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Departure of Radiotherapy, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Shanwen
authors.initials: S
authors.lastname: Zhang
keywords: Vascular epithelial growth factor (VEGF); advanced cancer; hyperthermia; radiotherapy; recombinant adenovirus-p53 (rAd-p53)